Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer

• Published in: Journal of surgical oncology 2015-11, Vol.112 (6), p.585-591
• Main Authors: Hur, Hoon, Kim, Young-Bae, Ham, In-Hye, Lee, Dakeun
• Format: Article
• Language: English
• Subjects: Acetate-CoA Ligase - metabolism; ACSS2; Adenocarcinoma - metabolism; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma, Mucinous - metabolism; Adenocarcinoma, Mucinous - mortality; Adenocarcinoma, Mucinous - pathology; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - metabolism; Carcinoma, Signet Ring Cell - metabolism; Carcinoma, Signet Ring Cell - mortality; Carcinoma, Signet Ring Cell - pathology; Female; Follow-Up Studies; gastric cancer; Humans; Immunoenzyme Techniques; Male; microsatellite instability; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; SIRT3; Stomach Neoplasms - metabolism; Stomach Neoplasms - mortality; Stomach Neoplasms - pathology; Survival Rate; Tissue Array Analysis; Young Adult
• ISSN: 0022-4790; 1096-9098
• DOI: 10.1002/jso.24043

Background Recent studies have demonstrated that acetyl‐CoA synthetase 2 (ACSS2) plays a critical role in cancer cell survival; however, the role of ACSS2 in gastric carcinogenesis has not been determined. Methods We investigated the expression of ACSS2 in human gastric cancer (GC) tissues using immunohistochemistry, and analyzed its clinicopathological correlation and prognostic relevance. Results Among 350 GCs, 219 cases (62.6%) were classified as ACSS2‐low, whereas 131 cases (37.4%) were ACSS2‐high. Loss of ACSS2 expression (ACSS2‐low) was more frequently observed in undifferentiated histology (P = 0.002), in cases with MLH1‐loss (P = 0.003), and in cases with SIRT3‐low (P